Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (95)	6/11/2001 5:02:53 PM
From: nigel bates	Respond to of 1005

BLUE HP wishing he'd caught this in real life You're not the only one. I traded out of MCLS at around $3.10, and was looking to get back in. Have been busy, so completely missed last week's announcement. Aaargh. At a glance, Elitra seem to be a pretty serious player. Plenty ex ABSC bods on the staff, and an exclusive deal with INCY (... and have collaborated with CRA) - Palo Alto, CA, and San Diego, CA, July 28, 2000 -- Incyte Genomics, Inc. (Nasdaq: INCY), a leading genomic information company, and Elitra Pharmaceuticals Inc., a leader in antimicrobial drug discovery and development announced today a collaboration in the field of antimicrobial genomics. Under the collaboration, Incyte will provide Elitra an exclusive license to Incyte’s PathoSeq™ microbial sequence database technologies to use as a platform for its functional genomics programs. In addition, Elitra will obtain the right to market and sell the PathoSeq database to third parties in collaboration with Incyte. As part of the collaboration, Incyte will receive equity in Elitra. Financial terms were not disclosed.